Clearside Biomedical (NASDAQ:CLSD) Given “Buy” Rating at HC Wainwright

Clearside Biomedical (NASDAQ:CLSD)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $6.00 price target on the stock.

Several other equities analysts have also weighed in on the stock. Chardan Capital reiterated a “buy” rating and issued a $6.00 target price on shares of Clearside Biomedical in a report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Clearside Biomedical in a research note on Thursday. Finally, StockNews.com raised Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Thursday, December 12th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $5.33.

Clearside Biomedical Stock Up 12.9 %

Shares of CLSD traded up $0.11 during midday trading on Thursday, reaching $0.96. The company had a trading volume of 804,558 shares, compared to its average volume of 399,340. Clearside Biomedical has a 1-year low of $0.77 and a 1-year high of $2.12. The firm has a 50 day simple moving average of $0.96 and a 200-day simple moving average of $1.06. The stock has a market cap of $72.81 million, a PE ratio of -2.13 and a beta of 2.10.

Institutional Investors Weigh In On Clearside Biomedical

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in Clearside Biomedical by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 764,058 shares of the company’s stock worth $726,000 after acquiring an additional 32,672 shares in the last quarter. Northern Trust Corp lifted its position in shares of Clearside Biomedical by 24.0% during the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock worth $157,000 after purchasing an additional 32,048 shares in the last quarter. Johnson & Johnson purchased a new position in shares of Clearside Biomedical in the third quarter valued at approximately $105,000. Finally, Investor s Fiduciary Advisor Network LLC acquired a new position in shares of Clearside Biomedical in the fourth quarter valued at approximately $32,000. 18.75% of the stock is owned by institutional investors and hedge funds.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.